Interleukin-based therapy for body weight control, energy homeostasis and TIIDM: Interleukin-2(IL-2) decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 7/June/2018, 6.38 am